Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis

Advances in Therapy, 2016 05; 33(5): 807-823. e-pub ahead of print 2016/04/17

he objective of this study was to examine healthcare resource utilization (HRU) and costs associated with switching to another tumor necrosis factor alpha inhibitor (TNFi) therapy versus a non-TNFi therapy among patients with rheumatoid arthritis (RA) discontinuing use of an initial TNFi biologic therapy.

View abstract

Authors

Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A.